Tut tut GSK
GlaxoSmithKline (GSK) has confirmed it is going to pay a massive fine after admitting it mis-promoted a range of drugs in the US.The pharmaceutical company stated that it will pay $105 million (£63 million) settlement with 44 US states and the District of Columbia following the way the firm promoted anti-depressants Paxil and Wellbutrin and asthma medication Advair.However, GSK did not admit any wrongdoing regarding the promotion of the medication and insisted that the money it is paying out is in relation to previous issues."We don't feel like this is who we are today," GSK spokeswoman Mary Anne Rhyne told the BBC. "Thes...
Source: PharmaGossip - June 5, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
Pharmalot 3.0 is back
Let joy be unbounded.http://blogs.wsj.com/pharmalot/ (Source: PharmaGossip)
Source: PharmaGossip - June 5, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
Globally, Pharma's Digital Spend is (Still) Only 6% of Total Promotional Budget
According to Cegedim Strategic Data (CSD) -- a provider of healthcare promotional audits -- in the last 6 months of 2013, the global pharma industry spent nearly $2.5 billion on all digital channels including pharma company websites, social media, web banner advertising in professional online journals and mobile apps.That works out to be approximately 6% of the total audited marketing expenditure, which includes "traditional, personal promotional channels;" i.e., sales reps.NOTE: I am uncertain if this CSD audit includes direct-to-consumer (DTC) promotional spending, which is only legal in the U.S. Also, keep i...
Source: Pharma Marketing Blog - June 4, 2014 Category: Pharma Commentators Tags: Cegedim Digital Pharma ePromotion marketing mix Source Type: blogs
WLF to FDA Regarding Distribution of Off-Label Reprints: See You in Court!
In February 2014, FDA released a new draft guidance document entitled "Distributing Scientific and Medical Publications on Unapproved New Uses - Recommended Practices." FDA's revised guidance is aimed at addressing some of industry's and the public's concerns regarding the previous guidelines by making clear that the pharmaceutical and medical device industries can distribute medical and scientific reprints -- including reprints of studies for new and unapproved uses of drugs -- to medical professionals, but only under certain conditions.In public comments submitted to FDA, the Washington Legal Foun...
Source: Pharma Marketing Blog - June 3, 2014 Category: Pharma Commentators Tags: FDA Guidance guidelines off-label promotion Reprints Source Type: blogs
Healthcare Marketers Trend Report 2014: I Give It a "C-Meh!" Rating
"Not all available market research is created equal," says Rich Meyer, author of DTC Marketing Blog. According to Meyer, "some research is a must have and provides insights, but there is also a lot of available research that doesn’t clarify findings and is written by journalists not people will real world pharma business experience." He goes on to rate various sources of pharma marketing research (here).Meyer has two ratings:"A-Must Have" and "D-Pass," which means don't bother with it. Meyer doesn't have a "C-Meh!" rating -- that's my way of saying "lackl...
Source: Pharma Marketing Blog - June 2, 2014 Category: Pharma Commentators Tags: Market Research marketing mix Media Mix Source Type: blogs
Pharma DTC Advertising Spend vs. Time Consumers Spend in Various Media
I came upon an interesting chart in Mary Meeker’s state-of-the-Internet slide deck. Meeker — formerly of Morgan Stanley, at VC firm Kleiner Perkins since late 2010 — each year produces a curated set of data reflecting what she sees as the major trends in Internet usage and growth. The chart (below) shows how American attention is divided among various forms of media and how that division lines up with where advertising dollars go, as I learned here. Click on chart for an enlarged view.I assume that the Ad Spending data reflect the average for all industries in the U.S. and the Time Spent in Media reflects what the av...
Source: Pharma Marketing Blog - May 29, 2014 Category: Pharma Commentators Tags: Ad Spend DTC Advertising Source Type: blogs
WikiCorrect-Health - Who, Who Are You! Who, who, who, who? 'Cause I really wanna know.
(Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - March 24, 2014 Category: Pharma Commentators Tags: Ethics social media transparency Wikipedia Source Type: blogs
Where did all the Prozac data go?
http://www.thesundaytimes.co.uk/sto/news/uk_news/Health/article1390959.ece Paywall (Source: PharmaGossip)
Source: PharmaGossip - March 24, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
Ketamine - A Professor Writes
For the past six months, I've fielded increasingly more questions about ketamine.My patients: "Will ketamine help me?" My colleagues: "Is ketamine safe for my patients?"Ketamine is an FDA- (Food and Drug Administration) approved drug for anesthesia during surgery and for pain relief -- in adults and children. Several studies (including one report published recently) have shown its rapid, positive effects in depression as well as rapid effects in obsessive-compulsive disorder (OCD) -- a persistent and often disabling disorder in which individuals have repetitive thoughts and behaviors.Because ketami...
Source: PharmaGossip - March 24, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
Annual Pharma Investment in "eSales," "eDetailing," "Virtual Detailing" … Whatever!
(Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - March 21, 2014 Category: Pharma Commentators Tags: eDetailing Sales and Sales Reps Virtual Detailing Source Type: blogs
Bob Marley - Small Axe
Why boasteth thyself, oh evil men,Playing smart and not being clever?I say you're working iniquity to achieve vanity, yeah,But the goodness of JAH JAH endureth forever.If you are the big tree,We are the small axe.Sharpened to cut you down,Ready to cut you down.These are the words of my master.Keep on telling meNo weak heart shall prosper,Oh, no they can't.And whosoever diggeth a pit, Lord,Shall fall in it, shall fall in it.Whosoever diggeth a pit shall bury in it,Shall bury in it.If you are the big tree,We are the small axeSharpened to cut you down,Ready to cut you down.And whosoever diggeth a pit shall fall in it, fall in...
Source: PharmaGossip - March 20, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
Risperdal - ARKANSAS COURT TOSSES $1.2B JUDGMENT AGAINST J&J BY CHUCK BARTELS ASSOCIATED PRESS
LITTLE ROCK, Ark. (AP) -- The Arkansas Supreme Court on Thursday overturned a $1.2 billion judgment against Johnson & Johnson in a lawsuit challenging the drugmaker's marketing of the antipsychotic drug Risperdal.The court ruled that the state improperly sued under a law that applies to health care facilities, not pharmaceutical companies.The ruling comes in an appeal of lawsuit filed by Arkansas against the drugmaker and subsidiary Janssen Pharmaceuticals. The state says the companies didn't properly communicate the drug's risks and marketed it for off-label use, calling the practices fraudulent.Johnson & Johnson ...
Source: PharmaGossip - March 20, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
Plavix and The Five O
Hawaii attorney general sues makers of drug Plavix alleging unfair and deceptive marketingHawaii Attorney General David Louie filed a lawsuit Wednesday in 1st Circuit Court against Bristol-Myers Squibb and Sanofi-Aventis, the manufacturers and distributors of the drug Plavix, alleging unfair and deceptive marketing of the blood-thinning drug to Hawaii consumers.The suit alleges that manufacturers of Plavix, a “blockbuster antiplatelet” drug aimed at preventing strokes and heart attacks, began questionable marketing of the drug back in 1998 for not disclosing information related to how certain g...
Source: PharmaGossip - March 20, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
Has NICE joined AllTrials?
The NICE boss has called for “more data transparency” from pharma in a bid to improve the relationship between the pharma and healthcare industries.Speaking at a summit held recently in London, the chief executive of the National Institute for Health and Care Excellence (NICE), Sir Andrew Dillon, called for “more data transparency” from the pharma industry to improve its relationship with the healthcare industry.Sir Andrew, who was speaking at the Economist Pharma Summit, said it would “great” if pharma companies could make evaluation information available before a drug was released on the market to ensure the ...
Source: PharmaGossip - March 19, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
Martha Rosenberg writes
This article was posted on Monday, March 17th, 2014 at 2:44pm and is filed underHealth/Medical, Pharmaceuticals. 0 0 51http://dissidentvoice.org/2014/03/big-pharma-helps-milk-lobby-with-dangerous-drug/? (Source: PharmaGossip)
Source: PharmaGossip - March 18, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
